Nuclear Medicine Software Companies

The nuclear medicine software market is projected to reach USD 1,491.55 million by 2030 from USD 970.03 million in 2025, at a CAGR of 9.0% from 2025  to 2030. The market focuses on digital tools designed to support key functions such as patient coordination, image acquisition, data processing, and diagnostic interpretation in nuclear medicine. Characterized by a consolidated competitive landscape, the market is shaped by the rising demand for solutions that streamline complex clinical workflows and meet strict regulatory requirements. Its expansion is driven by ongoing innovations in imaging technologies, along with image analysis and treatment planning solutions, the increasing global burden of chronic illnesses that benefit from nuclear diagnostics and theranostics, and the integration of artificial intelligence and advanced analytics to improve clinical accuracy and efficiency.

The growth of the nuclear medicine software market is due to the increasing adoption of advanced analytics, dosimetry solutions, cloud-native platforms, and mobile and remote access solutions. The shift toward more personalized and efficient care models has further propelled the use of software that enhances clinical workflows, supports treatment planning, and ensures compliance with safety and regulatory standards, particularly in the emerging field of theranostics. Ongoing technological advancements, including AI and mobile-enabled platforms, are enhancing data analysis, imaging precision, and remote access capabilities. As healthcare systems continue to evolve globally, there is a rising demand for flexible and dependable software that can integrate smoothly into medical infrastructure and support expanding diagnostic, therapeutic, and clinical research demands.

The nuclear medicine software market is influenced by two key strategies: the integration of AI and advanced analytics to enhance existing solutions, and strategic partnerships that expand access to advanced diagnostic solutions and streamline clinical workflows. Additionally, under technological innovations, theranostics—a combination of therapy and diagnostics using targeted radiopharmaceuticals—is significantly transforming the nuclear medicine software landscape. Theranostics is driving progress in imaging, treatment planning, personalized dosimetry, and workflow orchestration.

To know about the assumptions considered for the study download the pdf brochure

Businesses are rapidly integrating AI/ML capabilities into nuclear medicine solutions to improve diagnostic precision and workflow efficiency. For instance, GE HealthCare's 2024 launch of the Voluson Expert Series models 22, 20, and 18 showcases the expanding industry focus on AI-driven automation in nuclear medicine and other medical imaging fields. AI features reduce manual labor, evaluate complicated imaging data, and identify anomalies early, especially in complex specialties such as oncology. Similarly, the market is witnessing a surge in collaborations and partnerships. For example, the seven-year Care Alliance between GE HealthCare and Sutter Health, which was launched in 2024, aims to expand access to advanced imaging technologies throughout California. This initiative focuses on providing complete patient care and improving nuclear medicine infrastructure by using AI-integrated diagnostic tools across PET/CT, SPECT/CT, MRI, CT, and X-ray systems.

The nuclear medicine software market is consolidated and is dominated by key players holding the majority of the market share. The major players operating in this market are GE HealthCare (MIM Software Inc.) (US), Siemens Healthineers AG (Germay), Koninklijke Philips N.V. (Netherlands), Lantheus Holdings, Inc. (US), Brainlab AG (Germany),  Mirada Medical (UK), DOSIsoft SA (France), Bracco Group (Italy), Hermes Medical Solutions (Sweden), INVIA, LLC (US), Mediso Ltd. (Hungary), Canon Medical Systems Corporation (Japan), LabLogic Systems Ltd.(UK), Mirion Technologies (ec2 Software Solutions) (US), COMECER S.p.A.(Italy), RaySearch Laboratories(Sweden), UltraSPECT Inc. (US), Sectra AB (Sweden), Agfa-Gevaert Group (Belgium), and Perceptive(UK).

MARKET RANKING

The ranking of companies in the nuclear medicine software market has been determined through a market share analysis, conducted after thorough secondary research and validated by primary respondents. This ranking considers parameters such as revenue generated from the breadth and depth of product portfolios, innovation, and launches. Based on this analysis, the top players leading the market are GE HealthCare (MIM Software Inc.)(US), Siemens Healthineers AG (Germany), Koninklijke Philips N.V. (Netherlands), Lantheus Holdings, Inc. (EXINI Diagnostics AB)(US), Mirion Technologies (ec2 Software Solutions)(US). The combined strengths have driven over 70–80% of the market share. Several key players are transforming the nuclear medicine software landscape with advanced technologies that enhance diagnostic accuracy and clinical efficiency. GE HealthCare (US), in partnership with MIM Software, leverages AI and multimodal imaging to support improved cancer and heart disease diagnostics. Siemens Healthineers (Germany) enhances clinical decisions through software that automates image analysis and integrates data across systems. Philips (Netherlands) combines powerful imaging and real-time analytics with its IntelliSpace Portal, facilitating faster and more collaborative diagnoses. Lantheus(US), through EXINI Diagnostics, focuses on AI tools for prostate cancer imaging, aiding doctors in making more precise treatment decisions. Meanwhile, Mirion Technologies(US), via ec2 Software Solutions, supports operational efficiency with software that manages radiation safety and clinical workflows. Together, these companies are making nuclear medicine smarter, safer, and more connected.

Related Reports:

Nuclear Medicine Software Market by Software (Image Management, Workflow, PACS, Dosimetry, Treatment, AI/Analytics), Application (Diagnosis, Treatment, Theranostics, Research), Disease (Onco, Neuro, Cardio), End User & Region - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com